Clozapine reduced ligand-stimulated ErbB phosphorylation, with reported cellular IC50 values of approximately 47 μM for ErbB1 in U87MG cells and 16 μM for ErbB4 in rat cortical neurons. Responses depended on model and stimulation: A431 cells showed less inhibition with EGF, and 100 μM clozapine increased basal ErbB1 phosphorylation approximately twofold without EGF. [2]
Limited enhancement of dopamine D2 receptor surface expression
Cell-based study · HEK293T cells transiently expressing extracellular FLAG-tagged human D2 long receptor [1]
Clozapine produced a lower maximum surface-receptor enhancement than haloperidol or olanzapine in a 24 h concentration–response experiment. A separate multi-drug comparison did not find the clozapine group significantly different from vehicle. These are surface-expression endpoints, not binding affinity or functional agonism.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration–response as plotted in Figure 2C; explicitly reported clozapine concentrations include 3, 10 and 30 μM. Multi-drug comparison: 10 μM clozapine.
- Exposure duration
- 24 h
- Method
- Drug exposure followed by surface FLAG ELISA; vehicle and haloperidol/olanzapine comparators.
- Reported limits
- Vehicle composition is not specified in the selected procedures/caption. Individual lower concentrations are not transcribed from the curve.
Methods and source locations
Compound reported in the paper: Clozapine; Compound label in the paper: clozapine
Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.
Results: D2R surface expression after clozapine treatment; Figure 2C–F and caption; Experimental procedures: constructs, cell culture, FLAG ELISA and statistics; Discussion functional-assay limitation
Maximum clozapine-induced increase in cell-surface D2R relative to haloperidol response: Surface FLAG ELISA after 24 h; enhancement above vehicle normalized to response to 10 μM haloperidol; not percent total surface receptor. — Results paragraph for Figure 2C; Figure 2C caption
Lowest tested clozapine concentration with significant surface D2R enhancement vs vehicle in the concentration–response dataset: Dunnett multiple-comparison test; not an EC50. Figure 2C clozapine n = 50 at 10 μM, 12 at 3 and 30 μM, 6 at other concentrations; mean ± S.E. — Figure 2C caption
Surface D2R after 10 μM clozapine for 24 h in the broader APD comparison: Dunnett test; n = 32 for clozapine. Box plot uses median and full-range whiskers; separate dataset from Figure 2C. — Figure 2D caption
Partial inhibition of recombinant ErbB kinases
Biochemical assay · Commercial recombinant intracellular-domain ErbB1, ErbB2 and ErbB4 proteins; Tyr-Glu heteropolymer substrate [2]
Clozapine reduced phosphorylation of a synthetic substrate by truncated ErbB kinases under the authors’ non-reducing assay conditions. Inhibition remained partial over the tested range; a biochemical IC50 was not established.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–100 μM
- Exposure duration
- 30 min kinase reaction at 37 °C
- Method
- 4 mM ATP; synthetic substrate phosphorylation enzyme immunoassay.
- Vehicle
- 0.2% Triton X-100 in kinase reaction buffer; compounds dissolved in Triton X-100 for this assay.
- Reported limits
- Independent biological preparation count and a biochemical IC50 are not reported for Figure 5.
Methods and source locations
Compound reported in the paper: Clozapine; Compound label in the paper: CLZ
Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.
Materials and methods: Chemical compounds and In vitro kinase assay; Results: Direct inhibition of ErbB kinases; Figure 5 and caption
Lowest concentrations reported to significantly reduce recombinant kinase activity: Tyr-Glu substrate phosphorylation detected by phosphotyrosine enzyme immunoassay, 450 nm; one-way ANOVA/Tukey; n = 5 assay wells; mean ± SE. Thresholds are not IC50 values. — Results: Direct inhibition of ErbB kinases; Figure 5 and caption
Model-dependent inhibition of ligand-stimulated ErbB phosphorylation
Cell-based study · Human U87MG astroglioma cells (EGF/ErbB1); primary fetal rat cortical neurons (neuregulin-1/ErbB4); A431 cells as a limiting comparator [2]
Clozapine reduced ligand-induced ErbB phosphorylation in U87MG cells and cortical neurons. The reported cellular phosphorylation IC50 values differ between the two receptor/model combinations. EGF-stimulated A431 ErbB1 was less sensitive, limiting generalization across cell types.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–100 μM
- Exposure duration
- 20–30 min antipsychotic pretreatment, followed by 5 min ligand stimulation in shared phosphorylation methods.
- Method
- Immunoblotting after EGF (U87MG/A431) or neuregulin-1 (neurons), 30 ng/mL ligand.
- Vehicle
- DMSO; vehicle control and unstimulated negative control.
- Co-treatment
- Ligand challenge, not a second therapeutic drug.
- Reported limits
- Dose-specific pretreatment time within the shared 20–30 min range is not assigned; cultures are sister cultures, not independent animals.
Methods and source locations
Compound reported in the paper: Clozapine; Compound label in the paper: CLZ
Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.
Materials and methods: Chemical compounds, Cell culture, Neuron culture and Immunoblotting; Results: Clozapine-dose-dependent inhibition; Figure 3; SI Figure S4 (PDF p. 6); Discussion: controversial actions
EGF-induced Tyr1173 ErbB1 phosphorylation in U87MG cells: Immunoblot phospho-ErbB1 normalized to total ErbB1; n = 3 sister cultures; mean ± SE. Author-reported approximate IC50; not enzyme potency. — Results: Clozapine-dose-dependent inhibition; Figure 3a
Neuregulin-1-induced Tyr1284 ErbB4 phosphorylation in cortical neurons: Immunoblot phospho-ErbB4 normalized to total ErbB4; n = 3 sister cultures; mean ± SE. Author-reported approximate IC50. — Results: Clozapine-dose-dependent inhibition; Figure 3b
EGF-stimulated ErbB1 phosphorylation in A431 cells at 100 μM clozapine relative to EGF alone: Exact number reported in Discussion; SI Figure S4 inspected; n = 3 cultures, mean ± SEM per caption. No exact number inferred from curve. — Discussion: controversial actions; SI Figure S4, PDF p. 6
Opposite response of basal ErbB1 phosphorylation in A431 cells
Cell-based study · Human A431 epidermoid carcinoma cells without EGF stimulation [2]
In the absence of EGF, 100 μM clozapine increased basal ErbB1 phosphorylation approximately twofold. This contrary response restricts the claim that clozapine inhibits cellular ErbB1 signaling to the tested model and stimulation conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–100 μM; opposite response described at 100 μM
- Method
- Clozapine alone, without EGF; normalized phosphorylation immunoblot.
- Vehicle
- DMSO in shared chemical methods; 0 μM clozapine baseline.
- Reported limits
- SI Figure S5 does not separately specify exposure duration; the ligand-stimulation sequence is not assigned to this ligand-free experiment.
Methods and source locations
Compound reported in the paper: Clozapine; Compound label in the paper: CLZ
Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.
SI Figure S5 and caption, PDF p. 7; Discussion: controversial actions; shared Chemical compounds, Cell culture and Immunoblotting methods
Basal Tyr1173 ErbB1 phosphorylation in A431 cells at 100 μM clozapine relative to untreated baseline: Immunoblot phospho-ErbB1/total ErbB1; mean ± SEM, n = 3 cultures; **P < 0.01, one-way ANOVA/Tukey in S5. Approximate fold description reported in Discussion, not a digitized decimal. — Discussion: controversial actions; SI Figure S5 and caption, PDF p. 7